Related Experiment Video
Updated: Jan 28, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
Calcilytics inhibit the proliferation and migration of human prostate cancer PC-3 cells
Aya Yamamura1, Md Junayed Nayeem1, Motohiko Sato1
1Department of Physiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan.
Abstract:
The carcinogenesis and development of prostate cancer are mediated by enhanced Ca2+ signaling. In the present study, the pharmacological profile of the Ca2+-sensing receptor (CaSR) antagonists (calcilytics) was examined in human prostate cancer PC-3 cells. NPS2143 and Calhex 231 blocked extracellular Ca2+-induced increases in cytosolic [Ca2+]. NPS2143 and Calhex 231 inhibited cell proliferation (IC50 = 7.4 and 10.3 μM, respectively) and migration. The exposure to NPS2143 or Calhex 231 down-regulated CaSR protein expression. These results demonstrated that calcilytics inhibited cell proliferation/migration and down-regulated CaSR expression in human prostate cancer cells, suggesting their potential as novel therapeutic drugs for prostate cancer.
Insights
Calcilytics, Ca2+-sensing receptor antagonists, inhibit prostate cancer cell proliferation and migration. These compounds also down-regulate CaSR expression, indicating potential as novel prostate cancer therapeutics.
Area of Science:
- Oncology
- Molecular Pharmacology
- Cell Biology
Background:
- Prostate cancer development involves dysregulated calcium (Ca2+) signaling.
- The Ca2+-sensing receptor (CaSR) plays a role in cancer cell physiology.
- Targeting CaSR presents a potential therapeutic strategy for prostate cancer.
Purpose of the Study:
- To investigate the pharmacological effects of CaSR antagonists (calcilytics) on human prostate cancer cells.
- To evaluate the impact of calcilytics on cell proliferation, migration, and CaSR expression.
Main Methods:
- Utilized human prostate cancer PC-3 cells.
- Administered CaSR antagonists NPS2143 and Calhex 231.
- Assessed cytosolic Ca2+ levels, cell proliferation (IC50), and cell migration.
- Measured CaSR protein expression levels.
Main Results:
- NPS2143 and Calhex 231 effectively blocked extracellular Ca2+-induced Ca2+ influx.
- Calcilytics significantly inhibited PC-3 cell proliferation and migration.
- Exposure to NPS2143 or Calhex 231 led to decreased CaSR protein expression.
Conclusions:
- Calcilytics demonstrate anti-proliferative and anti-migratory effects in prostate cancer cells.
- These compounds down-regulate CaSR expression in prostate cancer.
- Calcilytics show promise as potential novel therapeutic agents for prostate cancer treatment.
Related Concept Videos
Cancer Cell Migration through Invadopodia
Cell Migration
Cell Migration
Feedback Inhibition
Cells Coordinate Growth and Proliferation
Abnormal Proliferation

